Periodontology 2000 · 2026
Diagnostic use of extracellular vesicles in dentistry.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cheng Yu-Chi, Keles Eren A, Wu David T, Walt David R
Аннотация
OBJECTIVES: To review the diagnostic potential of extracellular vesicles (EVs) in dentistry and evaluate the methodological, translatory, and clinical considerations relevant to their use in oral biofluids.
MATERIALS AND METHODS: This narrative review synthesizes current evidence on EVs in dental diagnostics, focusing on saliva, gingival crevicular fluid (GCF), and peri-implant crevicular fluid (PICF). The review examines EV nomenclature, specimen sources, pre-analytical handling, isolation and characterization methods, diagnostic benchmarks, and clinical evidence across major oral diseases.
RESULTS: EVs are promising biomarkers because they protect molecular cargo and may enrich disease-relevant signals relative to whole biofluids. Current evidence is strongest for oral squamous cell carcinoma, periodontitis, and peri-implant disease, where EV-associated proteins, RNAs, and microbe-derived signals have shown diagnostic potential. Saliva offers a noninvasive and accessible matrix, whereas GCF and PICF provide greater site specificity for localized disease. However, major barriers remain, including inconsistent nomenclature, co-isolation of non-vesicular particles, variability in sample collection and EV enrichment methods, limited assay standardization, and insufficient multi-site clinical validation.
CONCLUSIONS: Oral-fluid EVs represent a compelling but early-stage diagnostic platform in dentistry. Their successful translation will require rigorous methodological standardization, MISEV-aligned reporting, robust analytical and clinical validation, and deployment strategies suited to either point-of-care or centralized laboratory testing.
CLINICAL RELEVANCE: EV-based assays could support earlier, more objective, and minimally invasive diagnosis and monitoring of oral diseases, particularly periodontal disease, peri-implant disease, and oral cancer, if current technical and translational barriers are overcome.
MATERIALS AND METHODS: This narrative review synthesizes current evidence on EVs in dental diagnostics, focusing on saliva, gingival crevicular fluid (GCF), and peri-implant crevicular fluid (PICF). The review examines EV nomenclature, specimen sources, pre-analytical handling, isolation and characterization methods, diagnostic benchmarks, and clinical evidence across major oral diseases.
RESULTS: EVs are promising biomarkers because they protect molecular cargo and may enrich disease-relevant signals relative to whole biofluids. Current evidence is strongest for oral squamous cell carcinoma, periodontitis, and peri-implant disease, where EV-associated proteins, RNAs, and microbe-derived signals have shown diagnostic potential. Saliva offers a noninvasive and accessible matrix, whereas GCF and PICF provide greater site specificity for localized disease. However, major barriers remain, including inconsistent nomenclature, co-isolation of non-vesicular particles, variability in sample collection and EV enrichment methods, limited assay standardization, and insufficient multi-site clinical validation.
CONCLUSIONS: Oral-fluid EVs represent a compelling but early-stage diagnostic platform in dentistry. Their successful translation will require rigorous methodological standardization, MISEV-aligned reporting, robust analytical and clinical validation, and deployment strategies suited to either point-of-care or centralized laboratory testing.
CLINICAL RELEVANCE: EV-based assays could support earlier, more objective, and minimally invasive diagnosis and monitoring of oral diseases, particularly periodontal disease, peri-implant disease, and oral cancer, if current technical and translational barriers are overcome.